Clinical trial for monitoring anti-coagulation by anti-Xa activity

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035700

Enrollment

Unknown

Registered

2020-08-16

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients anticoagulated with heparin (unfractionated heparin or low molecular weight heparin) or rivaroxaban

Interventions

anti-Xa activity group:anti-Xa activity

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: All hospitalized patients who need to use heparin (unfractionated heparin or low molecular weight heparin) or rivaroxaban for anticoagulation.

Exclusion criteria

Exclusion criteria: melignant tumor, late stage, or others disease which cannot be cured; serious lung artery hypertession; Combined with severe bleeding tendency such as intracranial hemorrhage; combined with irreversible brain damage: ischemic hypoxic encephalopathy, metabolic encephalopathy, etc.; aged above 65 years or younger than 18 years; CPR time> 60 min; serious damage to central nervus system; forbidding to anti-coagulation therepy.

Design outcomes

Primary

Measure	Time frame
bleeding rate;aculsion rate;patients survival rate;time of ICU stay;the dose of red blood cells used by patients;	—

Countries

China

Contacts

Public ContactRui Tian

Shanghai General Hospital

thunder021@hotmail.com+86 13764035999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026